Bronchial thermoplasty: implementing best practice in the era of cost containment

Journal of Asthma and Allergy » Volume 2017:10 Pages 225—230

Laren D Tan,1 Nicholas Kenyon,2 Ken Y Yoneda,2 Samuel Louie2

1Division of Pulmonary, Critical Care, Hyperbaric and Sleep Medicine, Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, USA

Abstract: Increasing dependence on advanced technologies in the 21st century has created a dilemma between the practice and business of medicine. From information technology to robotic surgery, new technologies have expanded treatment possibilities and have potentially improved patient outcomes and safety. Simultaneously, their escalating costs limit access for certain patients and health care facilities. Nevertheless, medical decisions should not simply be based on cost. Input from physicians and other health care specialists as well as adherence to best practice position statements, are vital to implementing truly cost-effective strategies in medicine. Bronchial thermoplasty (BT), a US Food and Drug Administration approved bronchoscopy procedure in difficult-to-control persistent asthma, is a prime example of a new technology facing cost and implementation challenges. We discuss the specific indications and contraindications for BT and review recent real-world experiences that can provide the foundation for building a comprehensive asthma program that provides BT for difficult-to-control asthma patients who fail national guideline treatment recommendations after an adequate clinical trial of one. We also offer insight into the barriers to implementing a successful BT program and strategies for overcoming them.

Keywords: asthma, severe asthma, severe refractory asthma, biologic resistant asthma, BT

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Top story: The list of diseases linked to air pollution is growing | Science Ne… https://t.co/NpGbgxPSxf, see more https://t.…
1hreplyretweetfavorite
Interasma RT @Aller_MD: “Dupixent for Atopic Dermatitis Aims for EU Approval” https://t.co/tHqjNe1Bt2 https://t.co/GBO9AwFmN8
1hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: How to Use Your LinkedIn 'Following' List for Marketing Outreach | S… https://t.co/GI12wZmtHF, see more https://t.…
1hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: Bill Gates: More Tech Revolutions Are Coming, And They'll Change Eve… https://t.co/pFyfMleKVh, see more https://t.…
1hreplyretweetfavorite
Interasma RT @Aller_MD: Passive blood #anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction https://t.co/uF
1hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma